All News
Low Risk of TB with Secukinumab
JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f
Read Article
Mortality Risk in Rheumatoid Lung Patients
A Medicare claims analysis of rheumatoid arthritis (RA) patients showed that RA-associated interstitial lung disease (RA-ILD) was seen in nearly 5% of patients and was found to increase mortality risks, including respiratory and cancer mortality not explained by other factors.
Read Article
Factors Predictive of SLE Flare After HCQ Taper/Discontinuation
The benefits of hydroxychloroquine in lupus are many, but what if you were to withdraw HCQ?
Read more: https://t.co/r5iDXBEuQP https://t.co/LImqA9y8Dn
Links:
Dr. John Cush RheumNow ( View Tweet)
Epidemiologic study of #SLE from CDC & lupus registries estimates there are 204,295 SLE pts in USA (2018). Prevalence=72.8 SLE/100,000 and is 9 X higher in females than males (129 vs 14.6/100,000), especially among Ame Indians/Alaska Natives, Black females https://t.co/5yHVQ9UqZ4
Links:
Dr. John Cush RheumNow ( View Tweet)
My note to the FDA staff: https://t.co/n2Pr2Kzrre
Dr. Janet Woodcock DrWoodcockFDA ( View Tweet)
Toci led to poorer outcomes in this study. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial | The BMJ https://t.co/95zaq2CEUU
Dr Philip Robinson philipcrobinson ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz - Plasmablasts may be a useful biomarker; but is not generally available in clinical labs (must be done on fresh whole blood) @UTSWIMchief https://t.co/GlEKw0KD3O
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz common lab findings: hypergammaglobulinemia is common but elevated ESR/CRP are not. Most have elevated IgG4 serum levels @UTSWIMchief https://t.co/wR5FEqZTsX
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz commonly presents as major salivary and lacrimal gland enlargement, orbital disease, autoimmune pancreatitis, retroperitoneal (mass) fibrosis or tubulointerstitial nephritis. @UTSWIMchief
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - IgG4 Dz renal involvement; most common is tubulointerstitial nephritis
@UTSWIMchief https://t.co/q8dZbgmvfK
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Grand Rounds - Dr. Andres Quiceno on "IgG4 related Disease" Histologic criteria req >40% on IgG4/IgG cells @UTSWIMchief https://t.co/2kOioCdFiM
Dr. John Cush RheumNow ( View Tweet)
Being "busy" is about priorties and productivity.
Dr. John Cush RheumNow ( View Tweet)
Inequities in Telemedicine During COVID-19
Health equity in the telehealth age has assumed added importance since the COVID-19 pandemic began but what if you don't have access to reliable technology? The problem spreads beyond that though.
https://t.co/L8nvUbOqHA https://t.co/SZSmerQGEY
Links:
Dr. John Cush RheumNow ( View Tweet)
Osteoporosis in Men - is often unrecognized till they fracture. Risk factors for OP in men:
- Meds: steroids; PPI immunosuppressives
- Chronic renal disease
- Smoking, ^^alcohol
- Sedentary lifestyle
- Elderly
- Family history: Osteoporosis
https://t.co/V4P5wey070
Links:
Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA
Sponsored by Novartis Medical Affairs
Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts.
https://t.co/r5Cf4WS63s https://t.co/zN99Jo9bO0
Links:
Dr. John Cush RheumNow ( View Tweet)
Results from Cohort Hip & Cohort Knee study (early symptomatic hip OA pts) finds that 1/9 went on to receive hip replacement during the 10-year follow-up. Clinical hip and Xray (ROA) OA increased over 10 yrs - ROA 19% to 49%, and clinical hip OA 27% to 43% https://t.co/AJXlkAxZiF https://t.co/PSY4ueXOsC
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr Stanley Cohen has written a nice review of VTE with JAK inhibitors, points out that little/no risk during developmental trials, is not the same as a low risk seen with long term use in real world patients (older, higher BMI, more activity) https://t.co/0utVMqHdf9
Dr. John Cush RheumNow ( View Tweet)
Swedish Rheumatology Quality Register study of 46316 RA pts (322601 visits) shows RA has a higher risk of venous thromboembolism (RR 1.88;95% CI 1.65, 2.15) & this increased with disease activity (RR=2.03;1.73 to 2.38) (compared to remission). https://t.co/R59tLy8WGx
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Woodcock has been appointed the interim head of the FDA. President Biden has yet to nominate a new FDA commissioner. Dr. Woodcock is a rheumatologist and current Director of CDER at the FDA .https://t.co/Wk0auZ2pn1
Links:
Dr. John Cush RheumNow ( View Tweet)
Sign up to attend RheumNow Live--March 20 and 21. CME credits available
https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d
Links:
Dr. John Cush RheumNow ( View Tweet)
